Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Hold” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average rating of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $42.09.

Several brokerages have weighed in on KYMR. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 17th. B. Riley raised their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, July 9th. Finally, Oppenheimer reissued an “outperform” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a report on Wednesday.

Kymera Therapeutics Trading Up 8.5 %

Shares of KYMR stock opened at $42.30 on Friday. The business’s 50 day moving average is $33.94 and its two-hundred day moving average is $34.83. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31. The company has a market capitalization of $2.60 billion, a P/E ratio of -16.85 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. During the same period last year, the business posted ($0.70) EPS. The company’s revenue was up 8.4% on a year-over-year basis. As a group, equities analysts predict that Kymera Therapeutics will post -2.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total transaction of $593,433.00. Following the completion of the transaction, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 479,200 shares of company stock valued at $18,219,660. 15.82% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $78,000. Comerica Bank lifted its stake in shares of Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Ameritas Investment Partners Inc. lifted its stake in shares of Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after buying an additional 295 shares during the period. Virtu Financial LLC purchased a new position in shares of Kymera Therapeutics during the first quarter valued at approximately $207,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after buying an additional 5,002 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.